Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to deliver precision genetic medicines for patients. Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with delivery of genetic medicines, such as: dose related toxicity, off-target effects, immunogenicity, gene size and delivery limitations, bioavailability, ability to re-dose, and vector manufacturing complexity. The Company is advancing an internal pipeline focusing on a variety of diseases with its most advanced research in Duchenne’s Muscular Dystrophy (DMD). Code Bio also has research programs underway based on targeting data focused on the lungs, pancreas, and liver.
Location: United States, Pennsylvania, Hatfield Township
Employees: 11-50
Total raised: $85M
Founded date: 2020
Investors 3
| Date | Name | Website |
| 07.07.2021 | New Enterp... | nea.com |
| 06.02.2022 | Takeda Ven... | takeda.com |
| - | T1D Fund | t1dfund.or... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.06.2022 | Series A | $75M | - |
| 20.04.2021 | Seed | $10M | - |
Mentions in press and media 10
| Date | Title | Description |
| 09.06.2022 | Code Biotherapeutics Raises $75M in Series A | HATFIELD, PA, Code Biotherapeutics, a biotechnology company, announced its Series A financing of $75 million led by Northpond Ventures. >> Click here for more funding data on Code Biotherapeutics >> To export Code Biotherape... |
| 08.06.2022 | Code Biotherapeutics Raises $75 Million in Series A Financing | Code Biotherapeutics, a Greater Philadelphia, PA-based biotechnology company advancing targeted non-viral delivery of genetic medicines, raised $75M in Series A funding. The round was led by Northpond Ventures with participation from Amgen ... |
| 07.06.2022 | Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases | Greater Philadelphia, Pa., June 7, 2022 — Code Biotherapeutics, Inc., (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced its upsized and oversubscribed Series A financing of $75 ... |
| 07.06.2022 | 4BIO Capital Portfolio Company Code Biotherapeutics Closes Upsized and Oversubscribed $75 Million Series A Financing | Press Release 4BIO Capital Portfolio Company Code Biotherapeutics Closes Upsized and Oversubscribed $75 Million Series A Financing 7 June 2022 London & Greater Philadelphia – 4BIO Capital (“4BIO” or “the Group”), an international ventur... |
| 01.03.2022 | Code Biotherapeutics Announces Collaboration with Takeda | Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced a collaboration and option agreement with Takeda to leverage Code Bio’s proprietary targeted 3DNA® n... |
| 20.04.2021 | 4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics | Press Release 4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics 20 April 2021 LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies ... |
| 20.04.2021 | 4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has co-led a $10 million Seed financing round in Code Biotherapeutics... |
| 20.04.2021 | Code Biotherapeutics Launches with $10 Million in Seed Financing to Develop Therapies for Debilitating Genetic Diseases | Code Biotherapeutics, Inc., a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases, launches today with $10 million in financing and headquarters in the... |
| 09.11.2015 | NEA joins a $35M round for a Wellcome-backed gene therapy player | After posting some early clinical success with its first gene therapy project, University of Oxford spinout NightstaRx is looking to widen its pipeline of projects, recruiting venture giant New Enterprise Associates to pitch in on a $35 mil... |
| - | 4BIO Capital Portfolio Company Code Biotherapeutics Closes an Oversubscribed $75 Million Series A | 7 June 2022 |